(Total Views: 791)
Posted On: 02/02/2022 3:09:45 PM
Post# of 148885
new investors: the top 4 misinformation points
Long investors already know all this but the following 4 points of misinformation that you will encounter during due dilligence are as follows. If you do your own legwork, the current share price should then rise on its own back to the 5 to 10 dollar range as we wait for a) clinical results b) approval, c) revenue
TABLE OF CONTENTS
==================
1. FDA STATEMENT
2. SEC STATEMENT
3. AMBULANCE CHASER LAW FIRMS
4. SAFETY PROFILE IGNORED
1 of 4: FDA STATEMENT
a) INACURATE b) AUTHOR NOT IDENTIFIED c) NO RETRACTION d) TRIAL BOTCHED by FDA CHANGES e) FDA has the nerve to say trial did not meet endpoint when data clearly shows it was FDA BOTCHING that caused it.
FDA statement chastising CYDY and its overly active investment community lobbying was released during trading hours (?really?irresponsible) without anyone identifying themselves at the FDA; was based on only partial data submitted to them by CYDY (the additional pending data was impactful); the COVID trial was botched as FDA insisted stop weekly injections by week 2 but CYDY wanted week 4; result was a decline in patient health from week 2 to week 4; Thats the FDA misinformation that was not mentioned in the letter. FDA has never released a letter like this ever before and since -- and it was released during trading hours, so simple errors could result in catastrophic harm to CYDY/any company, a very amatuerish gaff one gaff after another with that letter.
2 of 4: SEC STATEMENT
NO SEC INVESTIGATION INTO CYDY -- SEC gathering of CYDY data misrepresented as an investigation into CYDY wrongdoing. Poorly worded SEC insists data gathering has nothing to do with any CYDY investigation. Bottom line: there is no evidence that SEC investigating CYDY wrongdoing.
3 of 4: AMBULANCE CHASER LAW FIRMS
NO SHAREHOLDER CLASS ACTIONS My own financial advisor alerted me to class action law suits against CYDY, I inquired and found these big law firms were well known "big" ambulance chasers, fishing for any disgruntled investors willing to fund any class action. This is business as usual with those types of law firms. There is no evidence of any class action suit involving CYDY and thier shareholders.
4 of 4: SAFETY PROFILE IGNORED
SAFETY PROFILE
Almost no news article mentions that Leronlimab is extremely safe, perhaps the biggest side effect is injection site irritation. In one trial, Leronlimab tested as having fewer side effects than the administered placebo. No mention of this in any articles. HIV continous testing on the order of a decade, much longer than most any new trial drug. This is a major point of misinformation, the safety profile.
====
Long investors already know all this but the following 4 points of misinformation that you will encounter during due dilligence are as follows. If you do your own legwork, the current share price should then rise on its own back to the 5 to 10 dollar range as we wait for a) clinical results b) approval, c) revenue
TABLE OF CONTENTS
==================
1. FDA STATEMENT
2. SEC STATEMENT
3. AMBULANCE CHASER LAW FIRMS
4. SAFETY PROFILE IGNORED
1 of 4: FDA STATEMENT
a) INACURATE b) AUTHOR NOT IDENTIFIED c) NO RETRACTION d) TRIAL BOTCHED by FDA CHANGES e) FDA has the nerve to say trial did not meet endpoint when data clearly shows it was FDA BOTCHING that caused it.
FDA statement chastising CYDY and its overly active investment community lobbying was released during trading hours (?really?irresponsible) without anyone identifying themselves at the FDA; was based on only partial data submitted to them by CYDY (the additional pending data was impactful); the COVID trial was botched as FDA insisted stop weekly injections by week 2 but CYDY wanted week 4; result was a decline in patient health from week 2 to week 4; Thats the FDA misinformation that was not mentioned in the letter. FDA has never released a letter like this ever before and since -- and it was released during trading hours, so simple errors could result in catastrophic harm to CYDY/any company, a very amatuerish gaff one gaff after another with that letter.
2 of 4: SEC STATEMENT
NO SEC INVESTIGATION INTO CYDY -- SEC gathering of CYDY data misrepresented as an investigation into CYDY wrongdoing. Poorly worded SEC insists data gathering has nothing to do with any CYDY investigation. Bottom line: there is no evidence that SEC investigating CYDY wrongdoing.
3 of 4: AMBULANCE CHASER LAW FIRMS
NO SHAREHOLDER CLASS ACTIONS My own financial advisor alerted me to class action law suits against CYDY, I inquired and found these big law firms were well known "big" ambulance chasers, fishing for any disgruntled investors willing to fund any class action. This is business as usual with those types of law firms. There is no evidence of any class action suit involving CYDY and thier shareholders.
4 of 4: SAFETY PROFILE IGNORED
SAFETY PROFILE
Almost no news article mentions that Leronlimab is extremely safe, perhaps the biggest side effect is injection site irritation. In one trial, Leronlimab tested as having fewer side effects than the administered placebo. No mention of this in any articles. HIV continous testing on the order of a decade, much longer than most any new trial drug. This is a major point of misinformation, the safety profile.
====
(20)
(0)Scroll down for more posts ▼
